Since 2008, the BPI Theater, a live, interactive amphitheater located at the heart of the BioProcess Zone (booth #375), provides biopharmaceutical professionals with a dedicated destination to meet, network, listen and learn about the latest scientific, technology, business, and financial trends impacting biopharmaceutical research, development, and manufacturing.
In 2018, this live, three-day, complimentary event consists of targeted panel discussions and individual presentations focusing on Emerging Therapies, Techniques, and Technologies
Tuesday, June 5
EMERGING THERAPIES: Cell & Gene Therapies, Viral Vectors/Vaccines, Manufacturing Strategies for Therapeutic Modalities, Capacity Challenges & Opportunities
BioProcess Insider Daily - One-on-One Live Executive Interviews
10:00 – 10:15am Dave Kenyon, Senior Director, Global Scientific and Technical Affairs, Patheon Biologics
10:15 – 10:30am Kevin Noonan, Partner, McDonnell Boehnen Hulbert & Berghoff LLP
10:30 – 10:45am Rory Mullen, VP, New Business, IDA Ireland
10:45 – 11:00am Andy Topping, CSO, FUJIFILM Diosynth Biotechnologies
Manufacturing Automation for Patient-Scale Cell Therapies
11:00 am - 11:20 am
Speaker: Nina Bauer, Associate Director, Autologous Cell Therapy Commercial Development, Lonza Pharma & Biotech
Acoustic Cell Processing - An Innovation in Cell Therapy Manufacturing
11:20 am - 11:40 pm
Speaker: Richard Grant, Chief Product Officer, FloDesign
A Platform Production Process for Manufacturing Viral Vector and Vaccine Therapeutics Using Vero Cells
11:40 am - 12:00 pm
Speaker: Sandhya S Buchanan, Director, Upstream Process Development, FUJIFILM Diosynth Biotechnologies
Therapeutic Modalities - Business and Manufacturing Strategies Impacting the Decision to Develop One Therapy Type vs. Another
12:00 pm - 1:00 pm
Moderator: Patricia Seymour, Senior Consultant, BioProcess Technology Consultants, Inc.
-John Lee, SVP, Pharmaceutical Development, decibel Therapeutics
-Michael Kaufman, SVP, CMC, Mersana Therapeutics
-Jennifer Michaelson, VP, Preclinical Research and Early Development, Cullinan Oncology
-Weichang Zhou, SVP, CTO, WuXi Biologics
Industry experts discuss different modalities to treat various diseases, their unique manufacturing challenges, and appropriate strategy decisions including:
-Access to Manufacturing Capacity - outsource or build
-20/20 - How prevalent will these therapies be by 2020
Feeding the Demand for Cell and Gene Therapy Production
1:00 pm - 2:00 pm
Moderator: Dan Stanton, Editor, BioProcess Insider
-Dr. David Brindley, University of Oxford and Harvard University
-Ohad Karnieli, CEO and Co-Founder, Atvio Biotech, ISCT Process and Product Development Co-Chair
FDA Commissioner Scott Gottlieb described regenerative medicines as being ‘no longer the stuff of science fiction’ last year, and a spate of approvals of CAR T-cell and gene therapies seems to prove this.
With both Big Biopharma and biotech throwing scientists and funds towards these next-generation therapies, CDMOs have jumped upon the opportunity and invested in capacity and expertise.In this discussion, we speak with some of these third-parties and ask how they are supporting this lucrative area: What they can offer biopharma firms, what technologies and processing expertise they bring, and how they and how they can help industry navigate these relatively untrodden production and regulatory paths.
The Development of a Next Generation Antibody-Drug Conjugate (ADC)
2:00 pm - 2:20 pm
Speaker: Ken Meek, VP, Business Development and Marketing, MabPlex International Co., Ltd.
For the full BioProcess Theater Schedule, please visit convention.bio.org/bioprocess-theater
Session ID: 5818